Vernalis acquires US rights to Moxatag

Vernalis Therapeutics has acquired the U.S. rights to Pragma Pharmaceuticals' Moxatag (amoxicillin) extended-release tablets.

PRESS RELEASE

BERWYN, Pa. — Vernalis Therapeutics has added a new drug to its portfolio. The company announced Friday that its parent company had acquired the U.S. rights to Pragma Pharmaceuticals’ Moxatag (amoxicillin) extended-release tablets. The company will oversee the drug’s sale, marketing and distribution in the U.S.

“The addition of Moxatag … further underscores Vernalis Therapeutics' commitment to building a commercial presence in the U.S. market,” the company’s SVP commercial operations Tom Parker said. “We look forward to re-launching the product in early 2016, and believe it will be a natural complement to our recently launched 12-hour codeine-based prescription medication, Tuzistra XR, as both products offer patients and physicians an extended-release alternative to existing treatments.”

Moxatag is meant to treat tonsillitis or secondary pharyngitis in adults and children 12 years of age and older.